OVERVIEW

American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting is organized by American Society of Gene and Cell Therapy (ASGCT) and will be held from May 12 - 15, 2020.

2020 Pre-Meeting Workshops: Monday, May 11

• CAR T and Immune Effector Cell Therapies: 8 a.m. - 12 p.m.
The CAR T and Related Immune Effector Cell Therapies Workshop will feature discussions of the current state of CAR T therapeutic approaches in light of recent FDA approvals with updates on clinical long term follow-up gene editing and going beyond autologous CAR-T cells for cancer.

• Clinical Trials Training: 8 a.m. - 12 p.m.
The Clinical Trials Training workshop I will address the development of early stage clinical trials, specifically covering the journey from preclinical development to clinical trial implementation and is intended primarily for early stage investigators.

• Commercialization I: 8 a.m. - 12 p.m.
The Commercialization workshop I will focus on the regulatory pathways to the commercialization of gene and cell therapy products with discussions covering the harmonization of global regulatory approaches.

• Stem Cell Therapies: 8 a.m. - 12 p.m.
The Stem Cell Therapies workshop will feature a diverse offering of presentations covering a broad array of topics in stem cell therapies, including scientific advances and clinical applications.

• Clinical Trials Training II: 1 - 5 p.m.
The Clinical Trials Training workshop II will provide an in-depth discussion, including case studies and first-hand accounts, of the development and launch of gene therapy clinical trials, both in academia and in commercial settings.

• Commercialization II: 1 - 5 p.m.
The Commercialization workshop II will focus on the unique challenges emerging technologies pose in designing acceptable business models to maximize patient access and discussions of value based pricing and reimbursement for gene therapies.

• Gene Editing: 1 - 5 p.m.
The Gene Editing workshop will provide an overview of current gene editing technologies and approaches, emerging uses and applications, with sessions highlighting junior investigators and clinical gene editing programs.

• Oncolytic Viruses: 1 - 5 p.m.
The Oncolytic Viruses workshop will feature overviews of the recent advances in oncolytics, including oncolytic viruses, cancer vaccines, and novel combination immuno-oncologic therapies.

• Viral Vector Development: 1 - 5 p.m.
The Viral Vector Development workshop will provide an in-depth discussion of the advances as well as the challenges in vector development and manufacturing, including GMP production.